{
  "Country": "PO",
  "PICOs": [
    {
      "Population": "Patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall survival, quality of life"
    },
    {
      "Population": "Patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nintedanib in combination with Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall survival, quality of life"
    },
    {
      "Population": "Patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed",
      "Outcomes": "Progression-free survival (PFS), overall survival, quality of life"
    },
    {
      "Population": "Patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Dual-drug chemotherapy based on platinum",
      "Outcomes": "Progression-free survival (PFS), overall survival, quality of life"
    }
  ]
}